Authors
Latest:
Optimizing the Value of Real-World Evidence ProjectsMark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.
Latest:
Protecting the Pipeline: Secure Communications Strategies to Thwart Espionage and Safeguard Sensitive Information and Intellectual PropertyIn an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.
Latest:
Navigating PV Divergence: Compliance Tips for New EntrantsWith small biotechs facing similar expectations as large pharma in drug safety and pharmacovigilance, despite less resources, identifying the key differences between US and EU requirements can help these companies craft a practical path to multi-region compliance.
Latest:
COVID and AMR: Crisis Reframes Antibiotics FightThe redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic RoadmapThe increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
Future-Ready Leadership: Redefining the Biopharma C-suite for an AI-Driven EraHow will the tasks of C-suite leaders be transformed by intelligent technologies?
Latest:
How MSLs Can Enrich Scientific Exchange with Customer InsightIn today‘s environment, medical science liaisons (MSLs) must call on digital solutions to make use of the right data and encourage the right conversations to take place.
Latest:
What the COVID-19 Vaccine Process Showed Us, and How It Can Impact the Future of Drug DevelopmentIndustry has shown it can overcome challenges en route to creating new therapies.
Latest:
How Prescribing Power Has Shifted Beyond PhysiciansNurse practitioners and physician associates are two of the fastest growing clinician groups.
Latest:
Improving Readiness for Volume-Based Procurement in ChinaVolume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.
Latest:
Building Crisis Management and Risk Mitigation Plans into Patient Support ProgramsIn simple terms, patient support programs help get medicines into the hands of people who need them.
Latest:
A Biosimilars Roadmap: Understanding Payer PerceptionsWith competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.
Latest:
No Half Measures: How Medical Affairs Can Maximize and Measure ValueEducation and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Latest:
Key Considerations for Senior Executives Related to Quality CultureExploring practical points to further understand and strengthen quality culture.
Latest:
Understanding the HCP: Patient-Level Data Proves ValuableEvaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.
Latest:
Embracing Generative AI: Why Its Disruption is Positive for PharmaThe new era of generative AI is poised to impact pharma marketing and engagement in powerful and lasting ways. But amid all the technological praise, what are the key considerations brand teams must navigate?
Latest:
Measuring Pharma’s Trust PerformanceThe core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
Latest:
The American Rescue Plan Act of 2021: Pharmaceutical Industry ImpactAssessing the implications for the pharma industry of the America Rescue Plan Act of 2021, which provides nearly two trillion dollars in funding for various government programs, including many related to public health.
Latest:
Billing Codes for DTx Would Open the Floodgates for Behavioral Health EquityApproval of Medicare and Medicaid coverage for digital therapeutics represents next step in advancing care for mental health patients.
Latest:
Emergency Use Authorization: What We’ve Learned Bringing COVID-19 Therapies to MarketPandemic forces pharma companies to work faster and smarter to meet hard deadlines.
Latest:
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based ProductsAs the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
